Company Overview
About Endeavor Biomedicines
Endeavor Biomedicines is a clinical-stage biotechnology company founded in 2022 and headquartered in Cambridge, Massachusetts, that is developing precision small-molecule medicines targeting the molecular drivers of fibrotic diseases and cancer. The company's scientific focus is on identifying and inhibiting protein targets that are specifically activated in disease states — particularly in idiopathic pulmonary fibrosis (IPF), a fatal scarring lung disease, and solid tumor oncology. Endeavor's platform emphasizes structural biology and medicinal chemistry to design compounds with high selectivity for disease-driving targets, minimizing off-target effects that have limited the tolerability of earlier investigational drugs. The company is led by CEO Tomas Kiselak and supported by a scientific advisory board of leading experts in fibrosis and cancer biology.
Business Model & Competitive Advantage
Endeavor Biomedicines raised a landmark $450M Series B in 2024 led by Arch Venture Partners and GV (Google Ventures), with participation from RA Capital Management, Bristol-Myers Squibb, and other prominent life sciences investors. This is one of the largest Series B financings in biotech history, reflecting the high unmet need in fibrosis and the investors' conviction in Endeavor's target selection and drug discovery platform. The company's lead program is an inhibitor of THY1 (also known as CD90) — a cell surface protein implicated in the activation of fibroblasts and cancer-associated stromal cells — which is advancing toward clinical trials in IPF and potentially in solid tumors with fibrotic stroma.
Competitive Landscape 2025–2026
Endeavor Biomedicines competes in the fibrosis drug development space alongside companies like United Therapeutics, Galapagos (partnered with Gilead), Pliant Therapeutics, and Bridge Biotherapeutics. IPF has an FDA-approved standard of care (pirfenidone and nintedanib) that slows disease progression but does not reverse fibrosis or significantly improve survival, representing a clear opportunity for transformative therapies. In oncology, the tumor microenvironment and cancer-associated fibroblasts are increasingly recognized as critical barriers to immunotherapy efficacy, creating a second major opportunity for Endeavor's anti-fibrotic target biology.
Key Differentiators
Emerging Innovator
Endeavor Biomedicines is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Compare Endeavor Biomedicines with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Endeavor Biomedicines? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Endeavor Biomedicines Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Endeavor Biomedicines vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →